Claims for Patent: 9,914,748

Summary for Patent: 9,914,748

Title:	Preparation of maytansinoid antibody conjugates by a one-step process
Abstract:	The invention provides a one-step process for preparing a cell-binding agent cytotoxic agent conjugate comprising contacting a cell-binding agent with a cytotoxic agent to form a first mixture comprising the cell-binding agent and the cytotoxic agent and contacting the first mixture comprising the cell-binding agent and the cytotoxic agent with a bifunctional crosslinking reagent, which provides a linker, in a solution having a pH of about 4 to about 9 to provide a second mixture comprising the cell-binding agent cytotoxic agent conjugate, wherein the cell-binding agent is chemically coupled through the linker to the cytotoxic agent, free cytotoxic agent, and reaction by-products. The second mixture is then optionally subjected to purification to provide a purified cell-binding agent cytotoxic agent conjugate.
Inventor(s):	Li; Xinfang (Newton, MA), Worful; Jared M. (Pittsburgh, PA)
Assignee:	IMMUNOGEN, INC. (Waltham, MA)
Application Number:	15/215,857
Patent Claims:	1. A process for preparing a cell-binding agent cytotoxic agent drug conjugate comprising the steps of: (a) contacting a cell-binding agent with a cytotoxic agent to form a first mixture comprising the cell-binding agent and the cytotoxic agent, then contacting the first mixture with a bifunctional crosslinking reagent comprising a linker, in a solution having a pH of 4 to 9 to provide a second mixture comprising (i) the cell-binding agent cytotoxic agent conjugate, wherein the cell-binding agent is chemically coupled through the linker to the cytotoxic agent, (ii) free cytotoxic agent, and (iii) reaction by-products; and (b) contacting the second mixture with the cytotoxic agent to form a third mixture; and then contacting the third mixture with the bifunctional crosslinking reagent at a pH of about 4 to about 9 to provide a fourth mixture. 2. The process of claim 1, wherein the process further comprises the step of: (c) purifying the fourth mixture to provide a purified cell-binding agent cytotoxic agent drug conjugate. 3. The process of claim 2, wherein step (b) is repeated one more time before step (c) is carried out. 4. The process of claim 2, wherein step (b) is repeated one or more times before step (c) is carried out. 5. The process of claim 4, wherein each repeated step (b) is carried out after about one or more hours following initial step (b). 6. The process of claim 2, wherein the fourth mixture is purified by subjecting the mixture to tangential flow filtration, selective precipitation, adsorptive filtration, adsorptive chromatography, non-absorptive chromatography, or a combination thereof, to purify the cell-binding agent cytotoxic agent conjugate from the free cytotoxic agent and reaction by-products. 7. The process of claim 6, wherein the fourth mixture is purified by subjecting the mixture to non-adsorptive chromatography. 8. The process of claim 6, wherein the fourth mixture is purified by subjecting the mixture to tangential flow filtration. 9. The process of claim 1, wherein the contacting in step (a) is effected by providing the cell-binding agent in a reaction vessel, adding the cytotoxic agent to the reaction vessel to form the first mixture comprising the cell-binding agent and the cytotoxic agent, and then adding the bifunctional crosslinking reagent to the first mixture. 10. The process of claim 2, further comprising holding the fourth mixture between steps (b)-(c) to release the unstably bound linkers from the cell-binding agent. 11. The process of claim 10, wherein the fourth mixture is held for 20 hours at a temperature of 2.degree. C. to 8.degree. C. 12. The process of claim 2, further comprising quenching the fourth mixture between steps (b)-(c) to quench any unreacted cytotoxic agent and/or unreacted bifunctional crosslinking reagent. 13. The process of claim 12, wherein the mixture is quenched by contacting the fourth mixture with a quenching reagent that reacts with the free cytotoxic agent. 14. The process of claim 13, wherein the quenching reagent is selected from the group consisting of 4-maleimidobutyric acid, 3-maleimidopropionic acid, N-ethylmaleimide, iodoacetamide, and iodoacetamidopropionic acid. 15. The process of claim 1, wherein the contacting in step (a) occurs in a solution having a pH of 7 to 9. 16. The process of claim 1, wherein the contacting in step (a) occurs at a temperature of 16.degree. C. to 24.degree. C. 17. The process of claim 1, wherein the contacting in step (a) occurs at a temperature of 0.degree. C. to 15.degree. C. 18. The process of claim 1, wherein the cell-binding agent is an antibody. 19. The process of claim 18, wherein the antibody is a monoclonal antibody. 20. The process of claim 19, wherein the antibody is a humanized monoclonal antibody. 21. The process of claim 18, wherein the antibody is selected from the group consisting of huN901, huMy9-6, huB4, huC242, trastuzumab, bivatuzumab, sibrotuzumab, CNTO95, huDS6, rituximab, an antibody that binds to Her2, an antibody that binds to epidermal growth factor receptor (EGFR), an antibody that binds to CD27L, an antibody that binds to EGFRvIII, an antibody that binds to Cripto, an antibody that binds to CD138, an antibody that binds to EphA2, an integrin targeting antibody, an antibody that binds to CD37, an antibody that binds to folate, an antibody that binds to Her3, and an antibody that binds to insulin-like growth factor 1 receptor (IGF1R). 22. The process of claim 18, wherein the antibody is huCD37-3 antibody. 23. The process of claim 18, wherein the antibody is trastuzumab. 24. The process of claim 1, wherein the cytotoxic agent comprises a thiol group. 25. The process of claim 1, wherein the cytotoxic agent is a maytansinoid. 26. The process of claim 25, wherein the maytansinoid is N.sup.2'-deacetyl-N.sup.2'-(3-mercapto-1-oxopropyl)-maytansine (DM1). 27. The process of claim 25, wherein the maytansinoid is N.sup.2'-deacetyl-N.sup.2'-(4-methyl-4-mercapto-1-oxopentyl)-maytansine (DM4). 28. The process of claim 1, wherein the cell-binding agent is chemically coupled to the cytotoxic agent via chemical bonds selected from the group consisting of disulfide bonds, acid labile bonds, photolabile bonds, peptidase labile bonds, thioether bonds, and esterase labile bonds. 29. The process of claim 1, wherein the bifunctional crosslinking reagent comprises an N-succinimidyl ester moiety, an N-sulfosuccinimidyl ester moiety, a maleimido-based moiety, or a haloacetyl-based moiety. 30. The process of claim 29, wherein the bifunctional crosslinking reagent is selected from the group consisting of N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP), N-succinimidyl 4-(2-pyridyldithio)pentanoate (SPP), N-succinimidyl 4-(2-pyridyldithio)butanoate (SPDB), N-succinimidyl-4-(2-pyridyldithio)2-sulfo butanoate (sulfo-SPDB), N-succinimidyl 4-(maleimidomethyl)cyclohexanecarboxylate (SMCC), PEG-mal, sulfo-Mal, and CX1-1. 31. The process of claim 1, wherein the solution in step (a) comprises sucrose. 32. The process of claim 1, wherein the solution in step (a) comprises a buffering agent selected from the group consisting of a citrate buffer, an acetate buffer, a succinate buffer, and a phosphate buffer. 33. The process of claim 1, wherein the solution in step (a) comprises a buffering agent selected from the group consisting of HEPPSO (N-(2-hydroxyethyl)piperazine-N'-(2-hydroxypropanesulfonic acid)), POPSO (piperazine-1,4-bis-(2-hydroxy-propane-sulfonic acid) dihydrate), HEPES (4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid), HEPPS (EPPS) (4-(2-hydroxyethyl)piperazine-1-propanesulfonic acid), TES (N-[tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid), and a combination thereof. 34. The process of claim 1, wherein the cytotoxic agent is DM1, the bifunctional crosslinking agent is SMCC, and the antibody is huCD37-3 antibody. 35. The process of claim 2, wherein the cytotoxic agent is DM1, the bifunctional crosslinking agent is SMCC, and the antibody is huCD37-3 antibody. 36. The process of claim 1, wherein the cytotoxic agent is DM1, the bifunctional crosslinking agent is SMCC, and the antibody is trastuzumab. 37. The process of claim 2, wherein the cytotoxic agent is DM1, the bifunctional crosslinking agent is SMCC, and the antibody is trastuzumab.

Details for Patent 9,914,748

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2031-03-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2031-03-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2031-03-29
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2031-03-29
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2031-03-29